AIMS/HYPOTHESIS: Ceramides and IL-6 have a role in immune-inflammatory responses and cardiovascular diseases, and are suggested to be involved in insulin and glucose metabolism. We sought to assess the associations of circulating levels of IL-6, TNF-alpha and high-sensitivity C reactive protein (hsCRP), which are inflammatory markers related to insulin resistance (IR), with the plasma lipid metabolites ceramides and diacylglycerols (DAG) in patients with CHD. METHODS: Cross-sectional analyses were carried out on data from 33 patients with CHD. Serum levels of the inflammatory markers and plasma lipid metabolites (lipidomics approach performed by ultra-performance liquid chromatography coupled to electrospray ionisation MS) were measured at the same time point as insulin resistance (IR) (HOMA-IR index). RESULTS: Serum circulating levels of IL-6 were strongly correlated with plasma ceramide concentrations (r = 0.59, p < 0.001). Adjustments for serum TNF-alpha or hsCRP levels, smoking, BMI, age, sex or HOMA-IR did not change the results (p < 0.001). After adjustments for the effect of serum inflammatory markers (TNF-alpha or hsCRP), HOMA-IR and BMI the correlation between plasma DAG and serum IL-6 (r = 0.33) was also significant (p < 0.03). In a linear regression model, circulating levels of both ceramides and TNF-alpha had a significant independent influence on circulating levels of IL-6, altogether accounting for 41% of its variation (p < 0.001). CONCLUSIONS/ INTERPRETATION: Our results strongly suggest that the link between ceramides, IR and inflammation is related to the inflammatory marker IL-6. Ceramides may contribute to the induction of inflammation involved in IR states that frequently coexist with CHD.
AIMS/HYPOTHESIS: Ceramides and IL-6 have a role in immune-inflammatory responses and cardiovascular diseases, and are suggested to be involved in insulin and glucose metabolism. We sought to assess the associations of circulating levels of IL-6, TNF-alpha and high-sensitivity C reactive protein (hsCRP), which are inflammatory markers related to insulin resistance (IR), with the plasma lipid metabolites ceramides and diacylglycerols (DAG) in patients with CHD. METHODS: Cross-sectional analyses were carried out on data from 33 patients with CHD. Serum levels of the inflammatory markers and plasma lipid metabolites (lipidomics approach performed by ultra-performance liquid chromatography coupled to electrospray ionisation MS) were measured at the same time point as insulin resistance (IR) (HOMA-IR index). RESULTS: Serum circulating levels of IL-6 were strongly correlated with plasma ceramide concentrations (r = 0.59, p < 0.001). Adjustments for serum TNF-alpha or hsCRP levels, smoking, BMI, age, sex or HOMA-IR did not change the results (p < 0.001). After adjustments for the effect of serum inflammatory markers (TNF-alpha or hsCRP), HOMA-IR and BMI the correlation between plasma DAG and serum IL-6 (r = 0.33) was also significant (p < 0.03). In a linear regression model, circulating levels of both ceramides and TNF-alpha had a significant independent influence on circulating levels of IL-6, altogether accounting for 41% of its variation (p < 0.001). CONCLUSIONS/ INTERPRETATION: Our results strongly suggest that the link between ceramides, IR and inflammation is related to the inflammatory marker IL-6. Ceramides may contribute to the induction of inflammation involved in IR states that frequently coexist with CHD.
Authors: Arja T Erkkilä; Ursula S Schwab; Vanessa D F de Mello; Tiina Lappalainen; Hanna Mussalo; Seppo Lehto; Virpi Kemi; Christel Lamberg-Allardt; Matti I J Uusitupa Journal: Eur J Nutr Date: 2008-07-29 Impact factor: 5.614
Authors: D E Laaksonen; L Niskanen; K Nyyssönen; K Punnonen; T-P Tuomainen; V-P Valkonen; R Salonen; J T Salonen Journal: Diabetologia Date: 2004-07-28 Impact factor: 10.122
Authors: William L Holland; Trina A Knotts; Jose A Chavez; Li-Ping Wang; Kyle L Hoehn; Scott A Summers Journal: Nutr Rev Date: 2007-06 Impact factor: 7.110
Authors: Jacob M Haus; Sangeeta R Kashyap; Takhar Kasumov; Renliang Zhang; Karen R Kelly; Ralph A Defronzo; John P Kirwan Journal: Diabetes Date: 2008-11-13 Impact factor: 9.461
Authors: William L Holland; Benjamin T Bikman; Li-Ping Wang; Guan Yuguang; Katherine M Sargent; Sarada Bulchand; Trina A Knotts; Guanghou Shui; Deborah J Clegg; Markus R Wenk; Michael J Pagliassotti; Philipp E Scherer; Scott A Summers Journal: J Clin Invest Date: 2011-04-01 Impact factor: 14.808
Authors: Hemant Kulkarni; Peter J Meikle; Manju Mamtani; Jacquelyn M Weir; Marcio Almeida; Vincent Diego; Juan Manuel Peralta; Christopher K Barlow; Claire Bellis; Thomas D Dyer; Laura Almasy; Michael C Mahaney; Anthony G Comuzzie; Harald H H Göring; Joanne E Curran; John Blangero Journal: J Lipid Res Date: 2014-03-13 Impact factor: 5.922
Authors: Jose A Chavez; M Mobin Siddique; Siew Tein Wang; Jianhong Ching; James A Shayman; Scott A Summers Journal: J Biol Chem Date: 2013-11-08 Impact factor: 5.157